KRT17 and pancreatic neoplasm: The findings demonstrated a significant correlation between the expression level of PAK2 and the enrichment scores of gemcitabine resistance gene sets Therefore, we have demonstrated that PAK2 can mediate gemcitabine resistance in pancreatic cancer, and genes regulated by PAK2, such as SPRR1B, KRT5, and KRT17, are the major mediators promoting resistance to gemcitabine chemotherapy.